Retinal neovascular diseases including neovascular age-related macular degeneration (AMD), diabetic macular edema and retinal vein occlusion are the most vision-threatening diseases among the developed world working-age population. Abzyme Therapeutics LLC and its collaborators, Drs. Yoonjee Park of The University of Cincinnati and Barb Rohrer of The Medical University of South Carolina, have been awarded a $1,657,994 Small Business Innovation Research (SBIR) Phase II Grant by the National Eye Institute (NIAID). This project entitled “Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases” is aimed at developing a potent and long-acting camelid-derived multi-specific antibody targeting both VEGF and extracellular MMP inducer (Emmperin/Basigin/CD147) to prevent choroidal neovascularization. #maculardegeneration #abzyme #VEGF #retinaldisease Read more here: https://hubs.ly/Q02nqBnx0
关于我们
Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy using proprietary antibody generation platforms. The company is located in the Eastern Pennsylvania biotechnology/pharmaceutical hub 30-miles west of Philadelphia. Unique to Abzyme is our proprietary and highly engineered eukaryotic in vitro antibody discovery/optimization platform based on yeast display self-diversifying libraries, rapid target-directed antibody affinity maturation in combination with a FACS single cell sorting approach to identify desired antibodies. Abzyme’s modular antibody discovery platform incorporates a real-time screening ability to select for key properties such as epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity and target-specificity. Today, the Company has over 60 proprietary and partnered programs in development in therapeutic and diagnostic areas including infectious diseases, immuno-oncology, ophthalmology, inflammation and central nervous system disorders.
- 网站
-
https://www.abzymetx.com
Abzyme Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Royersford，Pennsylvania
- 类型
- 私人持股
- 创立
- 2010
- 领域
- Antibody devlopment、Antibody optimization、Antibody engineering、Antibody production、Therapeutic antibody、Bispecific Antibody、T-cell engaging antibody、Camelid VHH antibody、Human recombinant antibody、Single domain antibody、Immunotherapy、Human VH、CNS、Modular Antibody、Central nervous system、Blood-brain barrier、pre-targeted immunotherapy、anti-digoxigenin antibody、DIG-directed bispecific antibodies和Opnthalmology
地点
-
主要
获取路线
321 Jones Boulevard
Suite 300
US，Pennsylvania，Royersford，19468
Abzyme Therapeutics员工
-
Steve Manobianco
Managing Director, PSG Life Sciences
-
James (Jim) Fendrick
President & CEO | Antibodies & Assays | Research Tools | Life Science | Biotechnology | C Level | Key Opinion Leader
-
Hiep Tran
Chief Scientific Officer | Antibody Discovery | Antibody Engineering | Immunotherapy | Entrepreneur |
-
Samantha Lacy
--
动态
-
Chief Scientific Officer | Antibody Discovery | Antibody Engineering | Immunotherapy | Entrepreneur |
Royersford, PA, October 29, 2024?– Abzyme Therapeutics LLC, a biotechnology company focused on developing innovative antibody-based therapies, announced today that it has been awarded U.S. Patent No. 12,116,411 for its groundbreaking anti-CD3 antibody technology. This patent solidifies Abzyme’s intellectual property position in the field of therapeutic antibody development and underscores its commitment to advancing novel cancer treatments. The newly patented antibodies exhibit a novel pH-dependent binding profile, demonstrating high affinity to human CD3 at acidic pH conditions found in solid tumors. This specificity minimizes off-target binding to normal tissues, a major challenge in antibody-based therapies. By leveraging the acidic tumor microenvironment, Abzyme’s antibodies??improves tumor targeting and while reducing toxicity. For further information and interest in licensing these novel anti-CD3 antibodies, please contact: Abzyme Therapeutics LLC Stephen Manobianco, MBA. Director of Business Development Phone: 610-205-9650 E-mail: [email protected]
-